Protecting tissue (bioprosthetic) heart valves in people with metabolic syndrome
Mitigation Strategies for Metabolic Syndrome-induced Bioprosthetic Heart Valve Degeneration
This project tries a special polymer coating to help tissue heart valves last longer in people with metabolic syndrome or type 2 diabetes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11296840 on NIH RePORTER |
What this research studies
I have a tissue (bioprosthetic) heart valve that can wear out faster if I have metabolic syndrome or diabetes. The team is testing a polymer called poly-2-methyl-2-oxazoline (POZ) applied to valve tissue to reduce protein sticking, sugar-related damage, oxidation, and calcium buildup. They will run lab tests using human serum, biochemical assays, and implants in Zucker diabetic fatty rats to see whether the coating lowers damage and calcification. If these experiments succeed, the approach could move toward use on surgical and transcatheter tissue valves for patients like me.
Who could benefit from this research
Good fit: People with metabolic syndrome or type 2 diabetes who need or already have a bioprosthetic (tissue) heart valve are the most relevant candidates for this work.
Not a fit: People with mechanical heart valves, valve problems not related to metabolic syndrome, or who are not eligible for bioprosthetic valves are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, the coating could make tissue heart valves last longer in patients with metabolic syndrome, reducing the need for repeat valve procedures.
How similar studies have performed: Early laboratory tests and rat-model experiments from this group have shown the POZ coating reduces protein damage and calcification, but the approach has not yet been tested in human clinical trials.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Ferrari, Giovanni — Columbia University Health Sciences
- Study coordinator: Ferrari, Giovanni
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.